Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
Did not discontinue treatment with MMB for any reason while enrolled in Studies GS US 352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
A negative serum or urine pregnancy test is required for female participants of childbearing potential
Female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
Any Grade 3 or 4 (common terminology criteria for adverse events \[CTCAE\] Version 4.03) non-hematologic toxicity in the prior study that the Investigator considers related to previous MMB use must have resolved, reverted to Grade 1, or reverted to Baseline within the 30 days from last MMB administration to Day 1 of this study
Any AE requiring MMB interruption during the prior study must have resolved, reverted to Grade 1, or reverted to Baseline within the 30 days from last MMB administration to Day 1 of this study
Ability and agreement to attend protocol-specified visits at the study site
Able to comprehend and willing to sign the informed consent form
You may not be if
Known hypersensitivity to MMB, its metabolites, or formulation excipients
Incomplete recovery from major surgery prior to Day 1 of this study
Pregnant or lactating females
Presence of greater than or equal to (\>=) Grade 3 (CTCAE Version 4.03) peripheral neuropathy
Known positive status for human immunodeficiency virus (HIV)
Known chronic active or acute viral hepatitis A, B, or C infection